$2M to local roads through allocation fund – News – Bedford Now

By Elena Meadows Journal Correspondent

ThursdayAug6,2020at12:20PM

More than $2 million will be funneled to local roads through the St. Joseph County Road Commissions allocation fund.

In a collaboration between the road commission and 12 of the countys 16 townships, the road commission contributes 50 percent toward improvements such as chip-seal and hot-mix asphalt. Townships contribute the other 50 percent.

"That is how you improve your local road network," road commission managing director John Lindsey told road commissioners at their meeting Wednesday.

Township contributions toward the program range from $10,000 to $159,400, as budgets allow.

Among the townships not participating this year, Sturgis Township is saving for a bigger project in 2021 and Burr Oak Township canceled participation due to COVID-19.

Lindsey made special note of 1.49 miles of asphalt overlay work recently performed in Fennells subdivision of Fawn River Township. The road commission put in half, taxpayers paid for a large portion through a special assessment district and the township funded the remainder.

Also on Wednesday, road commissioners discussed graffiti that had been painted near the intersection of Pulver and Floating Bridge roads in Flowerfield Township. Commissioners directed staff members that, as time permits, they should paint over any writing on roads the county maintains.

View post:

$2M to local roads through allocation fund - News - Bedford Now

Feds offer more protections to seals than humans – Boston Herald

Maines first shark-caused human fatality came as a shock to residents and vacationers alike, but the odds of that occurring in Massachusetts waters increase virtually daily, thanks to conservation efforts that have swelled both seal and shark populations.

Authorities have confirmed that a 63-year-old woman from New York City was killed by a great white shark on Monday while swimming with her daughter off Harpswell, Maines Bailey Island.

Julie Dimperio Holowach became the first known person to die from a shark attack in Maines history, Patrick Keliher, the states Marine Patrol Commissioner, said at a Tuesday press conference.

Holowach, wearing a wetsuit, was swimming with her daughter about 20 yards from the shore when she was attacked. Thankfully her daughter escaped injury.

A fragment of a shark tooth found in the area of the attack was later positively identified by a Massachusetts Division of Marine Fisheries official as belonging to a great white.

The only other confirmed shark attack in Maine occurred 10 years ago near Eastport.

Swimmers and boaters were urged to use caution near Bailey Island, and avoid swimming near schooling fish or seals.

Thats certainly easier to do along the Maine coast.

But off Cape Cod beaches? Not so much.

Years of federal protection efforts have caused a proliferation of grey and harbor seals on the Cape and South Shore, especially off the coast of Chatham.

And that in turn has attracted the sealsprimary predator, sharks, in mounting numbers.

Its actually amazing that since 2012, there have only been three shark attacks off Wellfleet and Truro, on the outer Cape. Two years ago, 26-year-old Arthur Medici was killed while boogie-boarding at Newcomb Hollow Beach in Wellfleet the first shark attack fatality in 82 years in Massachusetts.

While its difficult to assess how many sharks invade the Cape during the summer season, experts agree the seal population has reached staggering proportions.

Sharon Young, the marine issues field director for the Humane Society of the United States, told the Associated Press in a July 2019 interview that nearly 300,000 seals go back and forth between Canada and the U.S.

The Marine Mammal Protection Act allows states to assume the responsibility for conservation and management of a species once it reaches its optimum sustainable population.

However Young conceded that controlling Cape Cods seal population would be a daunting likely impossible task.

Thats because the 10,000 (seals) that are on a specific beach today are not the same 10,000 that might be there tomorrow.

Thats essentially the same answer aMassachusetts citizens group seeking ways to protect Cape Cod beachgoers from great white sharks received last year.

Peter Howell, a founder of the Seal Action Committee, wanted Congress to amend the federal Marine Mammal Protection Act so seals and other species can be removed from the laws list of protected animals if their populations have sufficiently rebounded.

Democratic Congressman Bill Keating, who represents Cape Cod, said at the time delisting seals from the protection act wouldnt change things. He reiterated Humane Society Field Director Youngs assertion that the migration of gray seals from Canada would quickly replace any vacuum.

So, beachgoers, seals and sharks are here to stay guests no less of the federal government which apparently values their welfare over its human constituentslives and limbs.

Read the original:

Feds offer more protections to seals than humans - Boston Herald

The Trailer For Hulu’s New Comedy Woke Is Like Sorry to Bother You in All the Best Ways – POPSUGAR

New Girl's Lamorne Morris stars in Hulu's upcoming comedy series Woke, and if you're still reeling over the ending of Sorry to Bother You, you might want to check it out ASAP. The series follows Keef (Morris), a cartoonist on the verge of success whose life gets turned upside down after police roughly detain him for a crime he didn't commit. Before the incident, Keef preferred to "keep it light" and ignore the thinly veiled racism all around him. But the misunderstanding leaves him rightfully shaken, and he sets out to incite some much-needed social and political change with the help of his cartoons come to life.

Keef's new outlook on the world following his encounter with the police causes him to hear voices and talk to inanimate objects that take on the appearance of characters from his cartoons. These voices encourage him to take action in response to the instances of police brutality and systemic racism that permeate his everyday life and challenge those around him to do the same. Inspired by the life of cartoonist Keith Knight, Woke confronts the struggles the Black community faces in America today and takes a look at the importance of identity and culture through a comedic lens.

Morris will star alongside T. Murph, Blake Anderson, and Saturday Night Live's Sasheer Zamata. Woke premieres on Hulu on Sept. 9. In the meantime, enjoy the full series trailer above!

Read more here:

The Trailer For Hulu's New Comedy Woke Is Like Sorry to Bother You in All the Best Ways - POPSUGAR

Impact of Covid-19 on Malignant Mesothelioma Market Market to Witness High Demand During 2020-2027 – Levee Report

An introduction to Malignant Mesothelioma Market Report

Marketo Graphics has released a new research report named as Malignant Mesothelioma Market 2020 to its extensive database. The report is inclusive of numerical data and certified data, which is gathered from certified sources and market experts. It includes and evaluates all the changes and shifts that are observed in the market and its supplementary markets. The provided information can, therefore, be used to improve and strengthen a firms standing in the Malignant Mesothelioma market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp, Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd, Nichi-Iko Pharmaceutical Co., Ltd

Interested in this Malignant Mesothelioma market report? Get your FREE sample now! https://www.marketographics.com/sample-enquiry-form/11681

By Drug TypePemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others

By AdministrationOral, Parenteral

By Distribution ChannelHospital Pharmacies, Retail Pharmacies, Oncology Centers

Estimating the potential size of the Malignant Mesothelioma industry

Industry experts conducting the study further estimate the potential of the Malignant Mesothelioma industry. Such information is important for firms looking to launch an innovative service or product on the market. Industry experts have measured the total volume of the given market. Researchers have calculated the industry in terms of sales by the competitors and end-user customers. Data on the entire size of the Malignant Mesothelioma market for a particular product or a service for the forecast period, 2019 to 2026 covered in the report makes it valuable. This information reveals the upper limit of the Malignant Mesothelioma industry for a specific product or service.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketographics.com/discount-enquiry-form/11681

Knowing the trends influencing the industry performance

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering:

United States

Europe

China

Japan

Southeast Asia

India

Browse complete Malignant Mesothelioma report description And Full TOC @ https://www.marketographics.com/industry-reports/malignant-mesothelioma-market

There are many questions the research attempts to answer:

Why Choose Marketo Graphics?

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketographics.com/checkout-form11681

To summarize, the global Malignant Mesothelioma market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:With reports from over 500 prominent publishers as well as daily updates on our collection, intended to empower companies and individuals catch-up with vital insights on industries operating across different geographies, along with the trends, share, size and growth rate of market verticals and numerous other services, we have our fingers dipped in just about everything market research-related. Besides meticulously curated research reports, our clients can also access our specialized services without any additional charges to gain vital market insights.

Contact Us:John WatsonHead of Business DevelopmentOffice No, 203 Chandan Nagar,Kharadi Pune, Maharashtra 411014Direct Line:+918484002482Visit our News Site:http://newssucceed.com

David is an Experience Business writer who regularly contributes to the blog, He specializes in manufacturing news

Originally posted here:

Impact of Covid-19 on Malignant Mesothelioma Market Market to Witness High Demand During 2020-2027 - Levee Report

Impact of Covid-19 on Malignant Mesothelioma Market to Witness High Demand During 2020-2027 – Research Newspaper

An introduction to Malignant Mesothelioma Market Report

Marketo Graphics has released a new research report named as Malignant Mesothelioma Market 2020 to its extensive database. The report is inclusive of numerical data and certified data, which is gathered from certified sources and market experts. It includes and evaluates all the changes and shifts that are observed in the market and its supplementary markets. The provided information can, therefore, be used to improve and strengthen a firms standing in the Malignant Mesothelioma market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp, Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd, Nichi-Iko Pharmaceutical Co., Ltd

Interested in this Malignant Mesothelioma market report? Get your FREE sample now! https://www.marketographics.com/sample-enquiry-form/11681

By Drug TypePemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others

By AdministrationOral, Parenteral

By Distribution ChannelHospital Pharmacies, Retail Pharmacies, Oncology Centers

Estimating the potential size of the Malignant Mesothelioma industry

Industry experts conducting the study further estimate the potential of the Malignant Mesothelioma industry. Such information is important for firms looking to launch an innovative service or product on the market. Industry experts have measured the total volume of the given market. Researchers have calculated the industry in terms of sales by the competitors and end-user customers. Data on the entire size of the Malignant Mesothelioma market for a particular product or a service for the forecast period, 2019 to 2026 covered in the report makes it valuable. This information reveals the upper limit of the Malignant Mesothelioma industry for a specific product or service.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketographics.com/discount-enquiry-form/11681

Knowing the trends influencing the industry performance

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering:

United States

Europe

China

Japan

Southeast Asia

India

Browse complete Malignant Mesothelioma report description And Full TOC @ https://www.marketographics.com/industry-reports/malignant-mesothelioma-market

There are many questions the research attempts to answer:

Why Choose Marketo Graphics?

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketographics.com/checkout-form11681

To summarize, the global Malignant Mesothelioma market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:With reports from over 500 prominent publishers as well as daily updates on our collection, intended to empower companies and individuals catch-up with vital insights on industries operating across different geographies, along with the trends, share, size and growth rate of market verticals and numerous other services, we have our fingers dipped in just about everything market research-related. Besides meticulously curated research reports, our clients can also access our specialized services without any additional charges to gain vital market insights.

Contact Us:John WatsonHead of Business DevelopmentOffice No, 203 Chandan Nagar,Kharadi Pune, Maharashtra 411014Direct Line:+918484002482Visit our News Site:http://newssucceed.com

Original post:

Impact of Covid-19 on Malignant Mesothelioma Market to Witness High Demand During 2020-2027 - Research Newspaper

Greater Bay | Shenzhen emerges as engine of Chinas tech frontier – Macau Daily Times

In the northern suburbs of tech city Shenzhen, a forest of tower cranes stand at the site of a cow farm that is being transformed into a scientific engine.Here, the Guangming Science City is taking shape. The cluster of scientific facilities and universities now lies at the heart of Chinas ambition to build the Guangdong-Hong Kong-Macau Greater Bay Area into a science and innovation center.According to the local government, the Guangming Science City has launched construction of 60 projects, involving total investments of 140 billion yuan (20 billion U.S. dollars).The Shenzhen Bay Laboratory, which focuses on biomedical research, is among the latest to settle in the tech park in June. So far, the lab has assembled 49 teams to carry out COVID-19 research, including on virus sequencing and antibodies, said Zhan Qimin, director of the lab.Labs and basic science facilities are also prospering in other parts of Guangdong Province, helping the manufacturing heartland in south China rise as a new destination for the countrys, even the worlds, researchers.In 2018, the China Spallation Neutron Source opened in Dongguan as a super microscope to observe the microstructure of matter. A neutrino observatory is under construction in Jiangmen City, and a high-intensity heavy-ion accelerator is being built in Huizhou City.China has been promoting joint development in the bay area, which comprises Hong Kong, Macau and nine cities in Guangdong. Last year, China issued a more specific development plan for the area. One of its major aims is to build an international innovation and technology hub.Zhong Hai, an official in charge of Shenzhens technological sector, said the construction of basic science installations will improve the overall innovation capacity of Shenzhen, which is better known for housing Chinas many tech firms like Huawei and Tencent.The construction of the innovation hub has already lured in many graduates from Hong Kong, according to Xinhua, which neighbors Shenzhen and boasts many universities.Sing Chan, who launched an e-commerce platform in Shenzhen, is busy assisting Hong Kong entrepreneurs who wish to set up their businesses on the Chinese mainland.Over half of the Hong Kong teams came to the mainland for software and engineering hardware projects, according to the young entrepreneur from Hong Kong, who has helped bring over 200 Hong Kong-invested companies and entrepreneurial teams into Shenzhen.Peter Ding, who founded a high-tech firm on robotic applications in Shenzhen, noted the bay areas manufacturing prowess, which can help high-tech firms efficiently realize their brainchild.They (tech firms) can rely on Shenzhen as a research and development center, assemble products in cities like Foshan and Dongguan and benefit from basic science research in Hong Kongs universities, Ding said. MDT/Xinhua

More here:

Greater Bay | Shenzhen emerges as engine of Chinas tech frontier - Macau Daily Times

AI is struggling to adjust to 2020 – TechCrunch

Andrea GaglianoContributor

2020 has made every industry reimagine how to move forward in light of COVID-19: civil rights movements, an election year and countless other big news moments. On a human level, weve had to adjust to a new way of living. Weve started to accept these changes and figure out how to live our lives under these new pandemic rules. While humans settle in, AI is struggling to keep up.

The issue with AI training in 2020 is that, all of a sudden, weve changed our social and cultural norms. The truths that we have taught these algorithms are often no longer actually true. With visual AI specifically, were asking it to immediately interpret the new way we live with updated context that it doesnt have yet.

Algorithms are still adjusting to new visual queues and trying to understand how to accurately identify them. As visual AI catches up, we also need a renewed importance on routine updates in the AI training process so inaccurate training datasets and preexisting open-source models can be corrected.

Computer vision models are struggling to appropriately tag depictions of the new scenes or situations we find ourselves in during the COVID-19 era. Categories have shifted. For example, say theres an image of a father working at home while his son is playing. AI is still categorizing it as leisure or relaxation. It is not identifying this as work or office, despite the fact that working with your kids next to you is the very common reality for many families during this time.

Image Credits: Westend61/Getty Images

On a more technical level, we physically have different pixel depictions of our world. At Getty Images, weve been training AI to see. This means algorithms can identify images and categorize them based on the pixel makeup of that image and decide what it includes. Rapidly changing how we go about our daily lives means that were also shifting what a category or tag (such as cleaning) entails.

Think of it this way cleaning may now include wiping down surfaces that already visually appear clean. Algorithms have been previously taught that to depict cleaning, there needs to be a mess. Now, this looks very different. Our systems have to be retrained to account for these redefined category parameters.

This relates on a smaller scale as well. Someone could be grabbing a door knob with a small wipe or cleaning their steering wheel while sitting in their car. What was once a trivial detail now holds importance as people try to stay safe. We need to catch these small nuances so its tagged appropriately. Then AI can start to understand our world in 2020 and produce accurate outputs.

Image Credits: Chee Gin Tan/Getty Images

Another issue for AI right now is that machine learning algorithms are still trying to understand how to identify and categorize faces with masks. Faces are being detected as solely the top half of the face, or as two faces one with the mask and a second of only the eyes. This creates inconsistencies and inhibits accurate usage of face detection models.

One path forward is to retrain algorithms to perform better when given solely the top portion of the face (above the mask). The mask problem is similar to classic face detection challenges such as someone wearing sunglasses or detecting the face of someone in profile. Now masks are commonplace as well.

Image Credits: Rodger Shija/EyeEm/Getty Images

What this shows us is that computer vision models still have a long way to go before truly being able to see in our ever-evolving social landscape. The way to counter this is to build robust datasets. Then, we can train computer vision models to account for the myriad different ways a face may be obstructed or covered.

At this point, were expanding the parameters of what the algorithm sees as a face be it a person wearing a mask at a grocery store, a nurse wearing a mask as part of their day-to-day job or a person covering their face for religious reasons.

As we create the content needed to build these robust datasets, we should be aware of potentially increased unintentional bias. While some bias will always exist within AI, we now see imbalanced datasets depicting our new normal. For example, we are seeing more images of white people wearing masks than other ethnicities.

This may be the result of strict stay-at-home orders where photographers have limited access to communities other than their own and are unable to diversify their subjects. It may be due to the ethnicity of the photographers choosing to shoot this subject matter. Or, due to the level of impact COVID-19 has had on different regions. Regardless of the reason, having this imbalance will lead to algorithms being able to more accurately detect a white person wearing a mask than any other race or ethnicity.

Data scientists and those who build products with models have an increased responsibility to check for the accuracy of models in light of shifts in social norms. Routine checks and updates to training data and models are key to ensuring quality and robustness of models now more than ever. If outputs are inaccurate, data scientists can quickly identify them and course correct.

Its also worth mentioning that our current way of living is here to stay for the foreseeable future. Because of this, we must be cautious about the open-source datasets were leveraging for training purposes. Datasets that can be altered, should. Open-source models that cannot be altered need to have a disclaimer so its clear what projects might be negatively impacted from the outdated training data.

Identifying the new context were asking the system to understand is the first step toward moving visual AI forward. Then we need more content. More depictions of the world around us and the diverse perspectives of it. As were amassing this new content, take stock of new potential biases and ways to retrain existing open-source datasets. We all have to monitor for inconsistencies and inaccuracies. Persistence and dedication to retraining computer vision models is how well bring AI into 2020.

See the original post here:

AI is struggling to adjust to 2020 - TechCrunch

Nanotechnology Textile Market Projected to Witness Vigorous Expansion by 2020-2026 | Nano Textile, Colmar, eSpin Technologies – Market Research Posts

QY Research has Published Latest Trending Report on Global Nanotechnology Textile Market

Los Angeles, United State, The report titledGlobal Nanotechnology Textile Industry Research Report, Growth Trends and Competitive Analysis 2020-2026is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Nanotechnology Textile market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Nanotechnology Textile market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Nanotechnology Textile market is carefully analyzed and researched about by the market analysts.

Request Sample Report and Full Report TOC:https://www.qyresearch.com/sample-form/form/2039838/global-nanotechnology-textile-industry

The Essential Content Covered in the GlobalNanotechnology Textile Market Report:

* Top Key Company Profiles.* Main Business and Rival Information* SWOT Analysis and PESTEL Analysis* Production, Sales, Revenue, Price and Gross Margin* Market Share and Size

Global Nanotechnology Textile Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Nanotechnology Textile market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Top Players of Nanotechnology Textile Market are Studied: , Nano Textile, Colmar, eSpin Technologies, FTEnE, Parker Hannifin, Schoeller Textil, Odegon Technologies, Shanghai Huzheng Nano Technology, Aspen Aerogel

The report provides a 6-year forecast (2020-2026) assessed based on how the Nanotechnology Textile market is predicted to grow in major regions likeUSA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segmentation by Type:, Nanocoated Textiles, Nanoporous Textiles, Fabrics Consisting of Nanofiber Webs, Composite Fibers Based on Nanostructures

Segmentation by Application:, Healthcare, Packaging, Sports and Leisure, Defense, Others

Reasons to Buy this Report:

Table of Contents

1 Report Overview1.1 Research Scope1.2 Top Nanotechnology Textile Manufacturers Covered: Ranking by Revenue1.3 Market Segment by Type1.3.1 Global Nanotechnology Textile Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)1.3.2 Nanocoated Textiles1.3.3 Nanoporous Textiles1.3.4 Fabrics Consisting of Nanofiber Webs1.3.5 Composite Fibers Based on Nanostructures1.4 Market Segment by Application1.4.1 Global Nanotechnology Textile Consumption by Application: 2015 VS 2020 VS 20261.4.2 Healthcare1.4.3 Packaging1.4.4 Sports and Leisure1.4.5 Defense1.4.6 Others1.5 Study Objectives1.6 Years Considered 2 Global Market Perspective2.1 Global Nanotechnology Textile Revenue (2015-2026)2.1.1 Global Nanotechnology Textile Revenue (2015-2026)2.1.2 Global Nanotechnology Textile Sales (2015-2026)2.2 Global Nanotechnology Textile Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 20262.2.1 Global Nanotechnology Textile Sales by Regions (2015-2020)2.2.2 Global Nanotechnology Textile Revenue by Regions (2015-2020)2.3 Global Top Nanotechnology Textile Regions (Countries) Ranking by Market Size2.4 Nanotechnology Textile Industry Trends2.4.1 Nanotechnology Textile Market Trends2.4.2 Nanotechnology Textile Market Drivers2.4.3 Nanotechnology Textile Market Challenges2.4.4 Nanotechnology Textile Market Restraints2.4.5 Primary Interviews with Key Nanotechnology Textile Players: Views for Future 3 Competitive Landscape by Manufacturers3.1 Global Top Nanotechnology Textile Manufacturers by Sales (2015-2020)3.1.1 Global Nanotechnology Textile Sales by Manufacturers (2015-2020)3.1.2 Global Nanotechnology Textile Sales Market Share by Manufacturers (2015-2020)3.1.3 Global 5 and 10 Largest Manufacturers by Nanotechnology Textile Sales in 20193.2 Global Top Manufacturers Nanotechnology Textile by Revenue3.2.1 Global Nanotechnology Textile Revenue by Manufacturers (2015-2020)3.2.2 Global Nanotechnology Textile Revenue Share by Manufacturers (2015-2020)3.2.3 Global Nanotechnology Textile Market Concentration Ratio (CR5 and HHI)3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Nanotechnology Textile as of 2019)3.4 Global Nanotechnology Textile Average Selling Price (ASP) by Manufacturers3.5 Key Manufacturers Nanotechnology Textile Plants/Factories Distribution and Area Served3.6 Date of Key Manufacturers Enter into Nanotechnology Textile Market3.7 Key Manufacturers Nanotechnology Textile Product Offered 3.8 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type4.1 Global Nanotechnology Textile Historic Market Review by Type (2015-2020)4.1.2 Global Nanotechnology Textile Sales Market Share by Type (2015-2020)4.1.3 Global Nanotechnology Textile Revenue Market Share by Type (2015-2020)4.1.4 Nanotechnology Textile Price by Type (2015-2020)4.1 Global Nanotechnology Textile Market Estimates and Forecasts by Type (2021-2026)4.2.2 Global Nanotechnology Textile Sales Forecast by Type (2021-2026)4.2.3 Global Nanotechnology Textile Revenue Forecast by Type (2021-2026)4.2.4 Nanotechnology Textile Price Forecast by Type (2021-2026) 5 Global Nanotechnology Textile Market Size by Application5.1 Global Nanotechnology Textile Historic Market Review by Application (2015-2020)5.1.2 Global Nanotechnology Textile Sales Market Share by Application (2015-2020)5.1.3 Global Nanotechnology Textile Revenue Market Share by Application (2015-2020)5.1.4 Nanotechnology Textile Price by Application (2015-2020)5.2 Global Nanotechnology Textile Market Estimates and Forecasts by Application (2021-2026)5.2.2 Global Nanotechnology Textile Sales Forecast by Application (2021-2026)5.2.3 Global Nanotechnology Textile Revenue Forecast by Application (2021-2026)5.2.4 Nanotechnology Textile Price Forecast by Application (2021-2026) 6 North America6.1 North America Nanotechnology Textile Breakdown Data by Company6.2 North America Nanotechnology Textile Breakdown Data by Type6.3 North America Nanotechnology Textile Breakdown Data by Application6.4 North America Nanotechnology Textile Breakdown Data by Countries6.4.1 North America Nanotechnology Textile Sales by Countries6.4.2 North America Nanotechnology Textile Revenue by Countries6.4.3 U.S.6.4.4 Canada 7 Europe7.1 Europe Nanotechnology Textile Breakdown Data by Company7.2 Europe Nanotechnology Textile Breakdown Data by Type7.3 Europe Nanotechnology Textile Breakdown Data by Application7.4 Europe Nanotechnology Textile Breakdown Data by Countries7.4.1 Europe Nanotechnology Textile Sales by Countries7.4.2 Europe Nanotechnology Textile Revenue by Countries7.4.3 Germany7.4.4 France7.4.5 U.K.7.4.6 Italy7.4.7 Russia 8 Asia Pacific8.1 Asia Pacific Nanotechnology Textile Breakdown Data by Company8.2 Asia Pacific Nanotechnology Textile Breakdown Data by Type8.3 Asia Pacific Nanotechnology Textile Breakdown Data by Application8.4 Asia Pacific Nanotechnology Textile Breakdown Data by Regions8.4.1 Asia Pacific Nanotechnology Textile Sales by Regions8.4.2 Asia Pacific Nanotechnology Textile Revenue by Regions8.4.3 China8.4.4 Japan8.4.5 South Korea8.4.6 India8.4.7 Australia8.4.8 Taiwan8.4.9 Indonesia8.4.10 Thailand8.4.11 Malaysia8.4.12 Philippines8.4.13 Vietnam 9 Latin America9.1 Latin America Nanotechnology Textile Breakdown Data by Company9.2 Latin America Nanotechnology Textile Breakdown Data by Type9.3 Latin America Nanotechnology Textile Breakdown Data by Application9.4 Latin America Nanotechnology Textile Breakdown Data by Countries9.4.1 Latin America Nanotechnology Textile Sales by Countries9.4.2 Latin America Nanotechnology Textile Revenue by Countries9.4.3 Mexico9.4.4 Brazil9.4.5 Argentina 10 Middle East and Africa10.1 Middle East and Africa Nanotechnology Textile Breakdown Data by Type10.2 Middle East and Africa Nanotechnology Textile Breakdown Data by Application10.3 Middle East and Africa Nanotechnology Textile Breakdown Data by Countries10.3.1 Middle East and Africa Nanotechnology Textile Sales by Countries10.3.2 Middle East and Africa Nanotechnology Textile Revenue by Countries10.3.3 Turkey10.3.4 Saudi Arabia10.3.5 U.A.E 11 Company Profiles11.1 Nano Textile11.1.1 Nano Textile Corporation Information11.1.2 Nano Textile Business Overview11.1.3 Nano Textile Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.1.4 Nano Textile Nanotechnology Textile Products and Services11.1.5 Nano Textile SWOT Analysis11.1.6 Nano Textile Recent Developments11.2 Colmar11.2.1 Colmar Corporation Information11.2.2 Colmar Business Overview11.2.3 Colmar Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.2.4 Colmar Nanotechnology Textile Products and Services11.2.5 Colmar SWOT Analysis11.2.6 Colmar Recent Developments11.3 eSpin Technologies11.3.1 eSpin Technologies Corporation Information11.3.2 eSpin Technologies Business Overview11.3.3 eSpin Technologies Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.3.4 eSpin Technologies Nanotechnology Textile Products and Services11.3.5 eSpin Technologies SWOT Analysis11.3.6 eSpin Technologies Recent Developments11.4 FTEnE11.4.1 FTEnE Corporation Information11.4.2 FTEnE Business Overview11.4.3 FTEnE Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.4.4 FTEnE Nanotechnology Textile Products and Services11.4.5 FTEnE SWOT Analysis11.4.6 FTEnE Recent Developments11.5 Parker Hannifin11.5.1 Parker Hannifin Corporation Information11.5.2 Parker Hannifin Business Overview11.5.3 Parker Hannifin Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.5.4 Parker Hannifin Nanotechnology Textile Products and Services11.5.5 Parker Hannifin SWOT Analysis11.5.6 Parker Hannifin Recent Developments11.6 Schoeller Textil11.6.1 Schoeller Textil Corporation Information11.6.2 Schoeller Textil Business Overview11.6.3 Schoeller Textil Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.6.4 Schoeller Textil Nanotechnology Textile Products and Services11.6.5 Schoeller Textil SWOT Analysis11.6.6 Schoeller Textil Recent Developments11.7 Odegon Technologies11.7.1 Odegon Technologies Corporation Information11.7.2 Odegon Technologies Business Overview11.7.3 Odegon Technologies Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.7.4 Odegon Technologies Nanotechnology Textile Products and Services11.7.5 Odegon Technologies SWOT Analysis11.7.6 Odegon Technologies Recent Developments11.8 Shanghai Huzheng Nano Technology11.8.1 Shanghai Huzheng Nano Technology Corporation Information11.8.2 Shanghai Huzheng Nano Technology Business Overview11.8.3 Shanghai Huzheng Nano Technology Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.8.4 Shanghai Huzheng Nano Technology Nanotechnology Textile Products and Services11.8.5 Shanghai Huzheng Nano Technology SWOT Analysis11.8.6 Shanghai Huzheng Nano Technology Recent Developments11.9 Aspen Aerogel11.9.1 Aspen Aerogel Corporation Information11.9.2 Aspen Aerogel Business Overview11.9.3 Aspen Aerogel Nanotechnology Textile Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)11.9.4 Aspen Aerogel Nanotechnology Textile Products and Services11.9.5 Aspen Aerogel SWOT Analysis11.9.6 Aspen Aerogel Recent Developments 12 Value Chain and Sales Channels Analysis12.1 Nanotechnology Textile Value Chain Analysis12.2 Sales Channels Analysis12.2.1 Nanotechnology Textile Sales Channels12.2.2 Nanotechnology Textile Distributors12.3 Nanotechnology Textile Customers 13 Estimates and Projections by Regions (2021-2026)13.1 Global Nanotechnology Textile Sales Forecast (2021-2026)13.1.1 Global Nanotechnology Textile Sales Forecast by Regions (2021-2026)13.1.2 Global Nanotechnology Textile Revenue Forecast by Regions (2021-2026) 13.2 North America Market Size Forecast (2021-2026)13.2.1 North America Nanotechnology Textile Sales Forecast (2021-2026)13.2.2 North America Nanotechnology Textile Revenue Forecast (2021-2026)13.2.3 North America Nanotechnology Textile Size Forecast by County (2021-2026) 13.3 Europe Market Size Forecast (2021-2026)13.3.1 Europe Nanotechnology Textile Sales Forecast (2021-2026)13.3.2 Europe Nanotechnology Textile Revenue Forecast (2021-2026)13.3.3 Europe Nanotechnology Textile Size Forecast by County (2021-2026) 13.4 Asia Pacific Market Size Forecast (2021-2026)13.4.1 Asia Pacific Nanotechnology Textile Sales Forecast (2021-2026)13.4.2 Asia Pacific Nanotechnology Textile Revenue Forecast (2021-2026)13.4.3 Asia Pacific Nanotechnology Textile Size Forecast by Region (2021-2026) 13.5 Latin America Market Size Forecast (2021-2026)13.5.1 Latin America Nanotechnology Textile Sales Forecast (2021-2026)13.5.2 Latin America Nanotechnology Textile Revenue Forecast (2021-2026)13.5.3 Latin America Nanotechnology Textile Size Forecast by County (2021-2026) 13.6 Middle East and Africa Market Forecast13.6.1 Middle East and Africa Nanotechnology Textile Sales Forecast (2021-2026)13.6.2 Middle East and Africa Nanotechnology Textile Revenue Forecast (2021-2026)13.6.3 Middle East and Africa Nanotechnology Textile Size Forecast by County (2021-2026) 14 Research Findings and Conclusion 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Author Details15.3 Disclaimer

About US

QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services.

Read this article:

Nanotechnology Textile Market Projected to Witness Vigorous Expansion by 2020-2026 | Nano Textile, Colmar, eSpin Technologies - Market Research Posts

Aerospace Nanotechnology Market Current Trends, Swot Analysis, Business Overview and Forecast by 2028 | Key Players: Airbus, Glonatech, Flight Shield,…

A recent report published by QMI on the aerospace nanotechnology market is a detailed assessment of the most important market dynamics. After carrying out a thorough research of aerospace nanotechnology market historical as well as current growth parameters, business expectations for growth are obtained with utmost precision.

Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-62977?utm_source=PF/SG

The study identifies specific and important factors affecting the market for aerospace nanotechnology during the forecast period. It can enable companies investing in aerospace nanotechnology market to change their production and marketing strategies in order to envisage maximum growth.

According to the report, the aerospace nanotechnology market has been segmented by product type (nanomaterials, nanotools, nanodevices), by end user (aircraft parts, fuselage structure, aero engine parts, aircraft electronic communication system, other).

Insights about regional distribution of market:The market has been segmented in major regions to understand the global development and demand patterns of this market. For aerospace nanotechnology market, the segments by region are North America, Asia Pacific, Western Europe, Eastern Europe, Middle East, and Rest of the World. During the forecast period, North America, Asia Pacific and Western Europe are expected to be major regions on the aerospace nanotechnology market.

North America and Western Europe have been dominant players in this market with the presence of major companies which have a strong infrastructure to boost aerospace &defense sector. In addition, some of the major countries like the US, France, UK, and Canada has been global exporters of aerospace &defense technologies due to established research & development centers, and others. Also, some of the major companies operating in aerospace nanotechnology market are headquartered in these regions.

The Asia Pacific region is estimated to register fastest growing aerospace nanotechnology market since some of the major economies like China, India, and South Korea are present in the region. In recent decades, these countries have witnessed strong government spending on defense infrastructure, as well as promoting air transport and space research. During the forecast period, the Middle East region is estimated to be a potential region for aerospace nanotechnology market in the aerospace and defense sector. It is estimated that Eastern Europe will have stable demand during the forecast period. Also, the rest of the world is expected to be an emerging market with increasing demand.

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

1. Airbus2. Glonatech3. Flight Shield4. Lockheed Martin5. Lufthansa Technik, tripleO Performance Solution6. Zyvex Technologies7. CHOOSE NanoTech8. General Nano9. HR TOUGHGUARD10. Metamaterial Technologies.

Make an Inquiry for purchasing this Report @https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-62977?utm_source=PF/SG

Market Segmentation:By Product Type:o Nanomaterialso Nanotoolso Nanodevices

By End User:o Aircraft Partso Fuselage Structureo Aero Engine Partso Aircraft Electronic Communication Systemo Other

By Region:North Americao North America, by Countryo USo Canadao Mexicoo North America, by Product Typeo North America, by End User

Western Europeo Western Europe, by Countryo Germanyo UKo Franceo Italyo Spaino The Netherlandso Rest of Western Europeo Western Europe, by Product Typeo Western Europe, by End User

Asia Pacifico Asia Pacific, by Countryo Chinao Indiao Japano South Koreao Australiao Indonesiao Rest of Asia Pacifico Asia Pacific, by Product Typeo Asia Pacific, by End User

Eastern Europeo Eastern Europe, by Countryo Russiao Turkeyo Rest of Eastern Europeo Eastern Europe, by Product Typeo Eastern Europe, by End User

Middle Easto Middle East, by Countryo UAEo Saudi Arabiao Qataro Irano Rest of Middle Easto Middle East, by Product Typeo Middle East, by End User

Rest of the Worldo Rest of the World, by Countryo South Americao Africao Rest of the World, Product Typeo Rest of the World, by End User

Objectives of this report:o To estimate the market size for the aerospace nanotechnology market on a regional and global basis.o To identify major segments in the aerospace nanotechnology market and evaluate their market shares and demand.

o To provide a competitive scenario for the aerospace nanotechnology market with major developments observed by key companies in the historic years.o To evaluate key factors governing the dynamics of the aerospace nanotechnology market and their potential gravity during the forecast period.

Reasons to Buy This Report:o Offers unique insights into the decision-making process for every possible segment that aids in strategic decision making.o Market size estimate of regionally and internationally focused aerospace nanotechnology market.o Unique research methodology based on the dynamics of the aerospace nanotechnology market.o Identification of major companies operating in the industry with key strategies adopted in recent yearso Exhaustive scope to help each stakeholder across the value chain of the aerospace nanotechnology market.

Customization:This study is customized to meet your specific requirements:o By Segmento By Sub-segmento By Region/Countryo Product Specific Competitive Analysis

Contact:

Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 144 439 0986Email:[emailprotected]Web:www.quincemarketinsights.com

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Read the original post:

Aerospace Nanotechnology Market Current Trends, Swot Analysis, Business Overview and Forecast by 2028 | Key Players: Airbus, Glonatech, Flight Shield,...

How studying genetics and lifestyle can shape a healthier MENA region – The European Sting

(Credit: Unsplash)

This article is brought to you thanks to the collaboration ofThe European Stingwith theWorld Economic Forum.

Author: Habiba Al Alsafar, Associate Professor, Department of Biomedical Engineering, Khalifa University of Science, Technology and Research (KUSTAR) & Elizabeth ODay, Founder and Chief Executive Officer, Olaris Inc

Diagnosing diseases can be complex, because illness is not a fixed state and has to be considered in context. We may be born with factors that predispose us to disease, but our lifestyle dictates if and when undesirable symptoms will manifest themselves.

For example, our middle-eastern forefathers were relatively healthier than us because of a nomadic lifestyle which was considerably more active. Our genes have remained unchanged in our recent history, yet the prevalence of a number of lifestyle diseases such as diabetes and obesity has risen in contemporary middle eastern countries. This is in part due to a shift towards more sedentary lifestyles. The environment and our lifestyles are working in concert with inherent elements (that is, the products of our genome) to contribute to the status of our health.

The intersection of genetics and lifestyle choices is playing an increasingly significant role in managing the health of middle eastern populations. The prevalence of chronic disease, in particular diabetes and its associated complications, is alarmingly high throughout the Gulf States. According to the 2017 report from the International Diabetes Federation, 11% of the population in the Middle East and North Africa (MENA) region has diabetes. Disturbingly, the prevalence is higher in the population of countries like the United Arab Emirates (UAE), where 19.3% of those between the ages of 20 and 79 have type-2 diabetes. A number of major co-morbidities are linked to diabetes and of these, cardiovascular disease is the highest cause of mortality in the UAE, accounting for 40% of mortalities. Non-communicable diseases (NCDs) in total are responsible for 77% of all deaths in the UAE. Both men and women are dying prematurely, resulting in a profound impact on families specifically and the community on the whole. The impact is not only limiting progress and development of the nation, it has a bearing on government spending as treating end-stage disease carries significant costs.

To manage the health of a nation we must shift our attention to examine both genetics and the impact of lifestyle choices.

A recent audit of the worlds genomic data showed that the predominant genomes in public databases belong to Europeans (81%), while only 0.08% of the genome inventory represents ancestries from Arab and Middle Eastern populations. The genomes of people of Asian and African ancestries at 14% and 3% respectively were also relatively low.

A breakdown of non-European genomic data samples

Image: Nature

As alluded to above, the genome is a key part of the puzzle that is required for understanding disease within a population. Efforts are clearly being made to increase our understanding of the genomes of people with middle eastern ancestries and the genomes from efforts in Kuwait, Qatar and the UAE are now available. It comes at a time when sequencing costs have plummeted and are no longer prohibitive. Innovation in genome sequencing technologies does not appear to be slowing, and continued reductions in the cost can be expected.

We have and continue to propose the need to develop collaborative linkages: locally, throughout the region and internationally. Collaboration needs to be encouraged and should involve all sectors of healthcare, including practicing physicians and paramedics, policy-makers and research scientists. It is only through coordinated efforts throughout the region that patients will ultimately be provided with the information that will enable individuals, and their care providers, to make informed decisions about their health and wellbeing. Importantly, strong local leadership is required, because as the Portuguese writer and Nobel laureate Jos Saramago put it: If you dont write your books, nobody else will do it for you. No one else has lived your life.

NCDs account for 77% of all deaths in UAE

Image: WHO

The paradigm shift in healthcare that personalized or precision medicine customizing medical treatment to the individual characteristics, needs and preferences of a patient during all stages of care represents has been made possible through the availability of large datasets compiled by healthcare systems, technological advancements in next-generation genome sequencing and the development of proper analytical tools to identify relationships in vast datasets.

This is a systems biology approach that uses genome, phenome and microbiome data to quantify the wellness of an individual and to provide indicators of their impending disease state. The Pioneer 100 Wellness Project (P100) was a longitudinal study in the US designed to test this approach. It that was conceived on the rationale that as the scale of personal data increases with the convergence of advances in electronic health records sets, big data analysis, individual measurement devices, and consumer-activated social networks, it would be possible to define early warning signs for human diseases. Although the opportunities for observing health transitions in P100 were limited, the results were sufficiently compelling that it has justified refinements for an extended study involving a larger population of more than 100,000 individuals.

Health and healthcareHow is the World Economic Forum bringing data-driven healthcare to life?

The application of precision medicine to save and improve lives relies on good-quality, easily-accessible data on everything from our DNA to lifestyle and environmental factors. The opposite to a one-size-fits-all healthcare system, it has vast, untapped potential to transform the treatment and prediction of rare diseasesand disease in general.

But there is no global governance framework for such data and no common data portal. This is a problem that contributes to the premature deaths of hundreds of millions of rare-disease patients worldwide.

The World Economic Forums Breaking Barriers to Health Data Governance initiative is focused on creating, testing and growing a framework to support effective and responsible access across borders to sensitive health data for the treatment and diagnosis of rare diseases.

The data will be shared via a federated data system: a decentralized approach that allows different institutions to access each others data without that data ever leaving the organization it originated from. This is done via an application programming interface and strikes a balance between simply pooling data (posing security concerns) and limiting access completely.

The project is a collaboration between entities in the UK (Genomics England), Australia (Australian Genomics Health Alliance), Canada (Genomics4RD), and the US (Intermountain Healthcare).

Although currently viewed as a radical shift, preemptive measures have been proposed since the turn of the last century. In 1903, motivated by concerns about the healthcare of his time, Thomas Edison said: The doctor of the future will give no medicine, but will interest his patient in the care of the human frame, in diet and in the cause and prevention of disease. Through the more than 100 years since this statement, preventative strategies have taken hold in some areas of medicine (such as immunization), but there is more to do. In the words of the 11th century Persian physician and polymath Avicenna, There are no incurable diseases only the lack of will. There are no worthless herbs only the lack of knowledge. There is certainly no lack of will, and our knowledge is only expanding.

Therefore, the opportunity to apply personal medicine practices in the UAE to prevent or delay the onset of disease will have substantial social and economic impacts. The American physcian and systems biologist Dr Leroy Hood has predicted that the wellness and prevention market will outgrow the healthcare market, in part due to economic modelling which suggests that the reactive therapeutic route is unsustainable for ageing populations. The time to act is now.

Read the original:

How studying genetics and lifestyle can shape a healthier MENA region - The European Sting

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – GlobeNewswire

Cell, Gene & Tissue-Based Therapy Developers Poised to Break Year-Over-Year Global Financing Records

WASHINGTON, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, Innovation in the Time of COVID-19. The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

As the voice of the sector globally, ARM regularly publishes sector data reports to showcase clinical and scientific progress, as well as advancements and remaining challenges in the policy environment surrounding cell, gene and tissue-based therapies. The report also includes updated metrics on fundraising and clinical trials from more than 1,000 therapeutic developers worldwide.

Highlights from the H1 2020 Global Sector Report include:

Janet Lambert, CEO of ARM, commented:The regenerative medicine and advanced therapy sector has shown remarkable resilience in the face of many new challenges posed by COVID-19. Most importantly, were continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. ARM will continue to work with our membership and with policymakers in the second half of 2020 to further advance these transformative technologies. We are committed to bringing these life-changing therapies to patients in need.

This report is the latest in ARMs series of global regenerative medicine sector reports, providing up-to-date metrics on financings and the clinical landscape, as well as expert commentary on key trends and progress in the field. The full report is availableonline here, with key sector metrics and infographicsavailable here. For more information, please visitwww.alliancerm.orgor contact Kaitlyn (Donaldson) Dupont atkdonaldson@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 360+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Read more from the original source:

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - GlobeNewswire

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth – marketscreener.com

Houston, Texas, Aug. 06, 2020 (GLOBE NEWSWIRE) --

Houston, Texas, August 6, 2020 Immatics N.V. (NASDAQ: IMTX; Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today announced the extension of its cell therapy manufacturing collaboration with The University of Texas Health Science Center at Houston (UTHealth), in Houston, Texas. The continued collaboration grants Immatics access to UTHealths state-of-the-art cGMP manufacturing infrastructure at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, enabling continued production and supply of Immatics specialized, cell-based product candidates for testing in multiple clinical trials. Maximum capacity of the facility is anticipated at 48 ACTengine T cell products per month. The new agreement will run until the end of 2024. Under the agreement, UTHealth will provide Immatics with exclusive access to three cGMP suites and support areas for the manufacturing of various Adoptive Cell Therapy (ACT) products. Therapeutic T cell production will be carried out by Immatics manufacturing personnel and will be supported by a UTHealth-Immatics joint quality team.

Steffen Walter, Ph.D., Chief Technology Officer at Immatics, commented: During the last five years, we have established a strong and productive partnership with UTHealth that has enabled the initiation of four ongoing clinical trials. As we remain focused on the development of our clinical pipeline, this extension of our collaboration with UTHealth will fulfill Immatics manufacturing needs for our early-stage ACT clinical programs for the next four years. Being able to rely on a partner with profound cell therapy expertise who is familiar with our technologies and can support cGMP cell therapy production is critical to ensuring the advancement of our clinical trials. We look forward to continuing this fruitful collaboration with the experts at UTHealth.

Fabio Triolo, D.d.R., M.Phil., Ph.D., The Clare A. Glassell Distinguished Chair and Director of the Cellular Therapy Core at UTHealth, added: Signing the extended contract with Immatics fits into our strategy at UTHealth of supporting the development of new treatments for patients in need. We therefore look forward to continuing our collaboration and further leveraging the potential of our manufacturing capabilities.

About Immatics ACT ProgramsACTengine is a personalized approach in which the patients own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics proprietary cancer targets which are then reinfused back into the patient. Immatics latest proprietary ACTengine manufacturing processes are designed to generate cell product candidates within a short six day manufacturing window and to deliver highly proliferative T cells, with the capability to infiltrate the patients tumor and function in a challenging solid tumor microenvironment. The process is designed to rapidly produce younger, better-persisting T cells capable of serial killing tumor cells in vitro. Immatics is further advancing the ACT concept beyond individualized manufacturing with its product class ACTallo which is being developed to generate off-the-shelf cellular therapies.

More information on the clinical trials can be found at the following links: https://immatics.com/clinical-programs/ and https://clinicaltrials.gov/.

- ENDS -Notes to Editors

About ImmaticsImmatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.

For regular updates about Immatics, visit http://www.immatics.com. You can also follow us on Twitter and LinkedIn.

About UTHealthEstablished in 1972 by The University of Texas System Board of Regents, The University of Texas Health Science Center at Houston (UTHealth) is Houstons Health University and Texas resource for health care education, innovation, scientific discovery and excellence in patient care. The most comprehensive academic health center in the UT System and the U.S. Gulf Coast region, UTHealth is home to Jane and Robert Cizik School of Nursing, John P. and Kathrine G. McGovern Medical School and schools of biomedical informatics, biomedical sciences, dentistry and public health. UTHealth includes The University of Texas Harris County Psychiatric Center, as well as the growing clinical practices UT Physicians, UT Dentists and UT Health Services. The universitys primary teaching hospitals are Memorial Hermann-Texas Medical Center, Childrens Memorial Hermann Hospital and Harris Health Lyndon B. Johnson Hospital. For more information, visit http://www.uth.edu.

About the Evelyn H. Griffin Stem Cell Therapeutics Research LaboratoryThe Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, which is part of the Cellular Therapy Core at UTHealth, has been Immatics manufacturing partner since 2015. The site is a U.S. Food and Drug Administration (FDA)-registered and inspected cGMP facility that has received accreditation from the Foundation for Accreditation of Cellular Therapy (FACT) as well as certification from the Clinical Laboratory Improvement Amendment (CLIA) and the College of American Pathologists (CAP).

Forward-Looking StatementsCertain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as may, should, expect, intend, will, estimate, anticipate, believe, predict, potential or continue, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management's control including general economic conditions and other risks, uncertainties and factors set forth in filings with the Securities and Exchange Commission (SEC). Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.

Go here to read the rest:

Immatics Extends Cell Therapy Manufacturing Collaboration with UTHealth - marketscreener.com

Impact of COVID-19 Outbreak on Canine Stem Cell Therapy Market Expected to Secure Notable Revenue Share During 2020-2026 – Research Newspaper

This Canine Stem Cell Therapy Market report includes worldwide topmost prime manufactures like (VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet) in terms of company basic information, Product Category, Sales (Volume), Revenue (Million USD), Price, Gross Margin (%), Price, Cost, Growth Rate, Import, Export, Market Share and Technological Developments. Canine Stem Cell Therapy Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the Canine Stem Cell Therapy market Size (Production, Value and Consumption). In the end, the Canine Stem Cell Therapy industry report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Canine Stem Cell Therapy[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2081893

Canine Stem Cell Therapy Market Report Offers Comprehensive Assessment Of 1) Executive Summary, 2) Canine Stem Cell Therapy Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Canine Stem Cell Therapy Market Background, 7) Canine Stem Cell Therapy industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Canine Stem Cell Therapy Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Canine Stem Cell Therapy Market:The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Stem Cells Autologous Stem cells

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2081893

The report offers in-depth assessment of the growth and other aspects of the Canine Stem Cell Therapy market in important countries (regions), including:

The Following Points Are Important In Performing A Competitive Assessment of Canine Stem Cell Therapy Market:

What will make the customer buy from this operation instead of the competition?

Comparison between the products/services to the competitors products/services of Canine Stem Cell Therapy market (Features, Service, Quality, Price, Distribution, And Brand).

List the companies involved in the production of these products/services.

Describe the Canine Stem Cell Therapy market concentration (Such As Large Number of Small Players or Small Number of Large Players).

Detail the Canine Stem Cell Therapy market prevailing competitive intensity (Fierce Competition or Live and Let-Live).

Describe the competitors facile Canine Stem Cell Therapy market entry (Can the Easy Entry of Competitors Drive down Prices in the Market?)

Describe the clients competitive strategies against competitors and their products of Canine Stem Cell Therapy market(Low Cost, Niche Market, Product Differentiation, Etc.).

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

Continued here:

Impact of COVID-19 Outbreak on Canine Stem Cell Therapy Market Expected to Secure Notable Revenue Share During 2020-2026 - Research Newspaper

UK housing is on the agenda. How do we really build back better? – Big Issue

In part one of a special investigation, we consider the government's move to make it easier for developers to create not-fit-for-purpose homes in office buildings

Britain is at a housing tipping point. Our need for social housing, built well and built quickly, has never been more urgent. There is less housing stock available, there is a need to find homes for the previously homeless to meet the laudable ambition currently sounded by the authorities, and there is a growing need for affordable new homes for many others. Quality and a good place to live are key.

However, last month Westminster housing secretary Robert Jenrick announced a change in legislation making it easier for developers to convert buildings like offices into residential units, a practice largely shown to produce shoddy homes that promote overcrowding. The government says this will help us build back from the Covid-19 crisis. It leaves the situation on the horns of a dilemma. Build quickly for now, or build correctly for tomorrow?

The extension of permitted development rights (PDR) means offices, shops and warehouses in England can now not only be repurposed for housing but also demolished entirely to build homes on the land without planning permission. It means developers can sidestep minimum space standards and arent beholden to Section 106 a requirement that they contribute to the local community, whether by creating a percentage of affordable housing or injecting cash into local amenities. Instead, they submit a prior approval notice to the local authority, who can only consider limited factors such as flood risk and traffic when deciding if the project can go ahead.

The idea is that the creation of something built to fit the national standards is streamlined. But the resulting homes are tiny flats as small as 13 square metres in some cases with poor ventilation and internal windows reducing privacy. Some have no windows at all.

New rules dont take into account what we have learned about housing from the Covid-19 crisis

When the Royal Institution of Chartered Surveyors (RICS) researched the issue in 2018, it concluded that these conversions come at a cost both financially and socially. At the time one resident in a Croydon office-to-residential conversion said that their building wasnt maintained and that the large number of children living there had no access to outdoor space where they could play. Another said that because the building wasnt built with residential use in mind, there was next to no noise insulation, impacting quality of life for those living inside.

Im speechless, one resident said. How can this be allowed in a civilised country? Its so wrong. The politicians who allowed this need to come and live here. Its a total nightmare.

Just 30 per cent of the homes created through extended PDR in the past met minimum space standards nearly 80 per cent were studios or one-bed units, compared to just 37 per cent of those created using the full planning permission process.

When compared to similar developments in Glasgow conversions in Scotland and Wales must still go down the planning route homes in the Scottish city were found to be much higher quality and better maintained, and had more space for families to live in. RICS concluded that easing up office-to-residential rules was a fiscal giveaway from the state to private real estate developers.

In fact, the PDR changes contradict the governments own research. The same week Jenrick made the announcement, the Ministry of Housing, Communities and Local Government published a report blasting office-to-residential conversions created without full planning permission as seeming to create worse quality residential environments than planning permission conversions in relation to matters of health, wellbeing and quality of life.

Its a policy that appears to produce a lot of housing quickly, says RICS associate director of planning and development Tony Mulhall, but housing with question marks all over it.

What I have seen when visiting conversions like these has shocked me, he says. People are expected to live without any natural light or space to move around.

Its no good having developers approach national standards as technicalities to comply to. Those standards are about function. Homes need to work for the people living in them or they shouldnt be built.

The idea of converting office buildings to homes is something that fits in with how our towns and cities are changing, he says and its likely office space will be less in demand in the future now that companies have discovered home working to be viable. We dont always have one area for offices, another for houses like we once did. And offices are often in really handy locations. If you can live close to where you work and shop close to where you live, that makes good sense. But those buildings are often just totally unsuitable to be converted.

Its an issue developers can exploit particularly in global cities like London, he adds, where many people are desperate for homes just to get a toehold in the area. The new rules dont take into account what we have learned about housing from the Covid-19 crisis that overcrowding is a danger to public health, and that outdoor space is vital. Instead of loosening restrictions, we should be thinking about how important the addition of a balcony can be to small flats, Mulhall says. And even when done well, these conversions dont turn out cheap.

Who are these homes going to be for? Thats something that should be asked more often, he says. Many of these units go into the private rental market, sometimes earmarked as affordable housing but in practice theyre very expensive. Research into office-to-residential conversions in Leeds and Leicester found they were mostly marketed as expensive student flats, doing little to meet local housing need. And last year it emerged that some of the 210,000 children whose families were caught up in the housingcrisis were moved into unsuitable converted office blocks as temporary accommodation.

New homes created through extended PDR have an impact on cash-strapped councils, too. RICS estimated that the financial impact to Englands local authorities was a net loss of around 50m. Around 42.5m of that came from the affordable housing contributions developers would have been required to make had they gone through the planning permission process. Councils are actively opposing the governments latest changes.

Councillor David Renard, housing spokesperson for the Local Government Association, tells The Big Issue: The planning system is not a barrier to housebuilding, with nine in 10 planning applications approved by councils. It gives local communities the power to shape the area they live in and provides an effective means of balancing the interests of homeowners and their neighbours.

Taking away the right of locals to have a say about what happens in their community deprives them of the ability to define the area they live in and know best, he says. It risks giving developers the freedom to ride roughshod over local areas with communities having no way of ensuring they meet high quality standards, provide any affordable homes as part of the development or ensure supporting infrastructure such as roads, schools and health services are in place.

RICS research also showed that PDR conversions made it more difficult for councils to meet local social housing need. Yet just days after Jenrick announced the changes for developers, a Westminster housing select committee released a report urging ministers to start building 90,000 social homes a year to beat Englands broken housing system.

Go here to see the original:

UK housing is on the agenda. How do we really build back better? - Big Issue

Calyxt will license its plant gene-editing tech to other firms – Minneapolis Star Tribune

Calyxt, a food technology company spawned by the University of Minnesota, said this week it will offer its gene-editing technology in licensing deals to other companies.

The company whose technology is known as TALEN and uses molecular scissors to remove undesirable traits in plants had until recently focused on contracting with farmers to grow their seeds and managing the manufacture of products made from the crops.

It is now in talks with several companies to license its technology or the specific traits in plants it has developed.

It would be a competitor to the CRISPR technology thats out there, but we believe we have a little cleaner commercialization plan with TALEN than what CRISPR has, said Travis Frey, the firms chief technology officer.

One high-profile example was high-oleic soybeans, which were converted into oil by a processor in Iowa and sold under the Calyxt brand Calyno.

In its new emphasis on licensing its technology and the traits it develops, Calyxt is pivoting away from managing the processing and sale of end products like oil, Frey said.

Most of the partners were looking at are probably going to put it under their own brand, Frey said. Theyre just much better at doing that, and the other thing is it helps us get revenue. We can earn cash sooner.

The publicly traded firm, launched in 2019, said it is in the advanced stages of developing improved-digestibility alfalfa, high fiber wheat, feminized and low THC hemp for fiber, food and CBD, gluten-free and cold-tolerant oats and pulses with improved flavor and protein.

Companies that want to develop products with that technology, or with traits developed by Calyxt, will now be able to secure a license.

Based in Roseville, the company got an exclusive license in 2015 to commercialize technology developed at the Us Department of Genetics, Cell Biology and Development.

Calyxt has not turned a profit since its inception and lost $39.6 million in 2019, but gene-editing is one of the hottest topics in agriculture.

Major seed companies are still working to dig out of the public relations and regulatory quagmire of genetically modified organisms, or GMOs. Gene-editing does not add foreign DNA to plants so the resulting products are not considered to be GMOs.

Follow this link:

Calyxt will license its plant gene-editing tech to other firms - Minneapolis Star Tribune

BMW launches its world-first eDrive Zones technology in the UK – Automotive World

As cities increasingly discuss the introduction of low emission zones, BMW is making another important contribution to boost the uptake and attractiveness of electromobility among consumers, by launching BMW eDrive Zones in London and Birmingham. With electric ranges of up to 54 miles, BMW plug-in hybrid models are built with cities in mind, as they can complete most commuting trips on pure-electric power. This new technology helps drivers do just that.

BMW eDrive Zones is a new digital service which automates the process of switching to electric-only power when a BMW plug-in hybrid vehicle enters a defined area of these cities. The service, unique in the worldwide automotive industry, also automatically ensures that the electric power is conserved for use during the part of the journey within the low emission zone, if the journey destination is entered into the vehicles navigation system.

This new technology ensures BMW plug-in hybrid models offer consumers the best of both worlds: electric-only driving in the city, where it makes the most difference and a highly efficient internal combustion engine to cover long distances.

This is the flexibility that customers want, as they make the transition to electromobility said Pieter Nota, BMW AG board member for Customer, Brands, Sales commenting on the UK launch of BMW eDrive Zones. A plug-in hybrid vehicle combines the best of two worlds: emission-free city-driving as well as long-distance capabilities. We urge governments to prioritise plug-in hybrid vehicles in order to encourage consumers to live a more sustainable lifestyle. BMW eDrive Zones technology supports customers to drive emission free in London and Birmingham. It improves air quality in cities fast and reduces running costs for drivers. Its win-win for everyone, Nota added.

The BMW eDrive Zones service, available as standard on BMW plug-in hybrid models running the latest BMW Operating System 7.0, uses geo-fencing technology via GPS within the vehicles navigation system. The eDrive Zones in London and Birmingham are highlighted graphically on the vehicles Central Control Display navigation screen, so drivers can see their location.

This feature, which is enabled in customer vehicles as of today, covers the same geographic area as the TFL Congestion Charge/ULEZ zone in London, whilst in Birmingham the service covers the citys planned Clean Air Zone, which is due to be implemented in 2021. BMW plans to introduce this technology in additional cities across the UK and Ireland in the future.

The BMW eDrive Zones service is now available as standard on BMW 330e, BMW 530e, BMW 745e and BMW X5 xDrive45e, with additional compatible models launching in the future. BMW eDrive Zones has also been made available via a free over-the-air software update for compatible BMW plug-in hybrid vehicles, meaning existing customers can also benefit from this technology.

The significant contribution plug-in hybrid vehicles can make to reducing tailpipe emissions in cities was demonstrated in an early trial of this technology, carried out in the Netherlands in 2018. Results of this research project showed 90 per cent of all routes within the trial zone in Rotterdam were driven in electric-only mode.

BMW Group production locations in the UK are also contributing towards the companys global electromobility goals. BMW Groups Hams Hall engine manufacturing plant, near Birmingham, assembles three-cylinder and four-cylinder petrol engines that are at the heart of a number of BMW and MINI plug-in hybrid vehicles. By the end of 2020, it is expected that one in five engines built by the company in Birmingham will be destined for a plug-in hybrid vehicle, rising to around 25 per cent of engines built next year.

At MINI Plant Oxford, the global centre of MINI manufacturing, production of the brands first battery-electric car started earlier this year. Last week, just before the plants annual summer shutdown, Plant Oxford hit a production milestone with 11,000 MINI Electric models built since production begun.

SOURCE: BMW Group

Follow this link:

BMW launches its world-first eDrive Zones technology in the UK - Automotive World

By Next Year, Will Doctors Finally Have The Technology To Fully Personalize Treatments For Lung Cancer Patients? – Forbes

Today, with the new risks posed by Covid, how do we provide the best care for people with non-Covid- related disease? For diagnosed cancer patients, these risks may warrant a re-evaluation of the common standards of treatment.

While targeted cancer therapies are now more tumor-specific and less toxic, and offer new possibilities for tailoring cancer treatment, there are still so many missing pieces: often as not, oncologists are shooting in the dark, trying to tailor the right treatment for their patient with very limited data. With the shadow of Covid, and the multiple risks cancer patients now face, clinicians are increasingly concerned.

"There are very few good biomarkers that enable personalized treatment regimens and therefore, in ... [+] most cases, we have a one size fits all approach."

Today, we use protocols to treat our patients with lung or other kinds of cancers, says Dr. Ofer Sharon, a longtime physician and entrepreneur. There are very few good biomarkers that enable personalized treatment regimens and therefore, in most cases, we have a one size fits all approach. Treatment starts following diagnosis and staging and we start to follow up on patients using clinical capabilities. Then what he describes is rather disturbing. Doctors are left to speculate as to which degree patients are responding to treatment. Usually, response assessment happens after three and six months. During this period, there are a lot of uncertainties, and sometimes there are adverse events and associated costs. If the patient is not responding the way we had hoped, we lose valuable time. There is a consensus among clinicians, he notes, that not all patients are the same and theres a dire need for effective tools to differentiate between patients and personalize treatment according to their needs.

OncoHost, an Israeli precision oncology company is now in the final steps of finalizing a host response profiling platform for predicting patient response to cancer therapeutics.

With over 20 years of experience in clinical and commercial product development for startups in the health tech, biotech, and medical device industries, Dr. Sharon decided to join OncoHost, as its CEO, following a personal tragedy. Seven years ago my father-in-law was diagnosed with advanced-stage melanoma. At the time, I was the medical director for Merck (MSD) and involved in the phase 3 trials of Keytruda, a drug that treats melanoma. Unfortunately, my father-in-law didnt meet the inclusion criteria for the trial and passed away three months before we launched the new drug. The frustration, which arises from the fact that in most cases we just dont know in time which patients will benefit from treatment and which will not, kept me awake for many nights.

When he came across Oncohost, he realized there might be hope for others. I was fascinated by the concept and science. The opportunity to make such a crucial difference in the way we treat cancer was something I just couldnt pass up, and I decided to take on this huge challenge.

The companys technology is based on high-throughput protein analysis, machine-learning algorithms, and bioinformatics tools. Its product, PROphetTM, is currently under study in a multi-center international clinical trial to predict patient response to immune-checkpoint inhibitors for non-small cell lung cancer and melanoma.

"Potential combination strategies and alternative treatments that may mitigate treatment ... [+] resistance." Dr. Ofer Sharon

So far, it has successfully identified a 10-protein signature that distinguishes between responders and non-responders to anti-PD-1 monotherapy or anti-PD-1 and anti-CTLA-4 combination therapy for melanoma. The technology should elucidate protein patterns associated with resistance to immune checkpoint inhibitors and will fulfill the need for differentiating responders from non-responders while monitoring the immune checkpoint inhibitor specific protein expression scores such as tumor proportion score.

The system, now in the clinical trial stage, analyzes the patients response and provides the patient and physician with a response prediction. In cases where no response is predicted, it suggests potential combination strategies and alternative treatments that may mitigate treatment resistance. "We hope this platform will like a CT or MRI add much-needed clinical information to support the complex and in many cases, life-and-death decision-making process".

The technology for assessing response to lung cancer therapy is expected to become available in the U.S. by next year.

Read this article:

By Next Year, Will Doctors Finally Have The Technology To Fully Personalize Treatments For Lung Cancer Patients? - Forbes

JinkoSolar reshapes PV technology scenarios with its new N-Type Tiger Pro 610W unveiled at SNEC 2020 – PRNewswire

SHANGRAO, China, Aug. 7, 2020 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or "Company") (NYSE: JKS) one of the world's largest and most innovative module manufacturers in the world, today launched its new generation of 610W Tiger Pro High-efficiency monocrystalline TR solar module and its BIPV solutions, Building Integrated Photovoltaics product series, which will be unveiled at SNEC 2020 in Shanghai.

As a PV company that has ranked first in global modules shipments for four consecutive years, JinkoSolar has always been committed to providing global customers with high-efficiency, top quality, and extremely reliable solar modules. The key behind the success of Tiger Pro 610W is the N-Type HOT 2.0 high-efficiency cell technology, independently developed by JinkoSolar. Thanks to the introduction of new technologies, such as HOT tunneling layer passivated contact and advanced metallization, the cell efficiency has reached 24.79%, setting once again a world record for the efficiency of large area N-Type monocrystalline silicon solar cells. At the same time, the use of 78 cell design and of TR technology, which helps reduce significantly the cell gap, as well as lower the electricity cost and improve the system compatibility, represents another milestone for the PV industry in its quest for grid parity.

JinkoSolar's module series have continuously broken the conversion efficiency record, starting from 2018, JinkoSolar Eagle PERC high-efficiency monocrystalline series, with a power of 390W and a conversion efficiency of 19.8%, followed by the Tiger HOT 1.0 high-efficiency monocrystalline series delivering a power output up to 475W and a conversion efficiency of 20.87%. The newest Tiger Pro HOT2.0, high-efficiency monocrystalline series, with its maximum output of 610W and a conversion efficiency of 22.3%, is setting once again new-standards for the industry and positioning JinkoSolar far ahead from its competitors.

Moreover, thanks to the great improvements made with the smart combination "PV + Architecture", during this edition of SNEC, JinkoSolar also unveiled its first version of colored BIPV module series.With a power output of up to 550W, this product series is available in a variety of colors and levels of translucence, incorporating modern architectural aesthetics for use as a building component.

Dr. Jin Hao, CTO of JinkoSolar, commented: "Reducing costs and increasing efficiency is the goal that the industry has always been striving for. JinkoSolar has always been committed to providing global customers with high-efficiency, top quality, and extremely reliable solar modules. We will increase our investment in R&D to ensure constant innovation in our technology, improve our products performance, and ensure the highest system compatibility. This will allow us to fulfill our commitment to offer the best service to our global customers and to allow the application of our solar modules in a variety of scenarios, further empowering the solar PV industry and achieving grid parity."

About JinkoSolar Holding Co., Ltd.

JinkoSolar (NYSE: JKS) is one of the largest and most innovative solar module manufacturers in the world. JinkoSolar distributes its solar products and sells its solutions and services to a diversified international utility, commercial and residential customer base in China, the United States, Japan, Germany, the United Kingdom, Chile, South Africa, India, Mexico, Brazil, the United Arab Emirates, Italy, Spain, France, Belgium, and other countries and regions. JinkoSolar has built a vertically integrated solar product value chain, with an integrated annual capacity of 17.5 GW for mono wafers, 10.6 GW for solar cells, and 16 GW for solar modules, as of March 31, 2020.

JinkoSolar has over 15,000 employees across its 7 productions facilities globally, 14 overseas subsidiaries in Japan, South Korea, Vietnam, India, Turkey, Germany, Italy, Switzerland, United States, Mexico, Brazil, Chile and Australia, and global sales teams in China, United Kingdom, France, Spain, Bulgaria, Greece, Ukraine, Jordan, Saudi Arabia, Tunisia, Morocco, Kenya, South Africa, Costa Rica, Colombia, Panama, Kazakhstan, Malaysia, Myanmar, Sri Lanka, Thailand, Vietnam, Poland and Argentina.

To find out more, please see: http://www.jinkosolar.com

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends, "plans," "believes," "estimates" and similar statements. Among other things, the quotations from management in this press release and the Company's operations and business outlook, contain forward-looking statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Further information regarding these and other risks is included in JinkoSolar's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. Except as required by law, the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

For investor and media inquiries, please contact:

Ms. Ripple ZhangJinkoSolar Holding Co., Ltd.Tel: +86 21-5183-3105Email: [emailprotected]

SOURCE JinkoSolar Holding Co., Ltd.

http://www.jinkosolar.com

See the original post here:

JinkoSolar reshapes PV technology scenarios with its new N-Type Tiger Pro 610W unveiled at SNEC 2020 - PRNewswire

What is China’s New Infrastructure Plan and Will it Benefit Tech Investors? – China Briefing

Building new infrastructure ( or for short) has recently become a top development priority for China and refers to infrastructure that is digital, smart, and innovative.

As part of its post-COVID-19 relief package, China is ramping up plans to construct new digital infrastructure across the country including building 5G networks, artificial intelligence (AI), Internet of Things (IoT), intercity high-speed rail, and setting up research and development institutions.

In doing so, a new wave of government support for private sector participation can be seen through the issuance of special bonds, encouraging public-private partnerships, or extension of credit support.

These plans work in concert with Chinas other industrial policies like Made in China 2025 and China Standards 2035 Plan which together signal Chinas ambitious long-term strategy of becoming the global leader in high-tech and innovative industries of the future.

New opportunities now exist for early investors looking to participate in these fast-growing technology industries and subsectors. In addition, large industry players have the chance to invest in projects that will propel the commercialization of emerging technology.

Foreign investors should continue to follow-up on the latest policy developments in their target area of investment, as more government policies will likely be released shortly to guide the development of each of these new technologies.

In this article, we explain what we know about Chinas new infrastructure plan so far, along with the opportunities for investors to get involved.

At the 2020 National Peoples Congress, the CCP announced that in addition to doubling down on itsMade in China 2025andChina Standards 2035 initiatives, it would spend approximately US$1.4 trillion on a digital infrastructure public spending program.

The new infrastructure includes seven key areas: 5G networks, industrial internet, inter-city transportation and rail system, data centers, AI, ultra-high voltage power transmission, and new-energy vehicle charging stations.

Originally touted as a way for China to achieve domain independence and accelerate its industrial upgradation, the new infrastructure plan has transformed into a long-term national economic strategy.

However, in April 2020, the National Development and Reform Commission released a revised categorization of new infrastructure to include three broad aspects of next-generation technology:

Infrastructure with public benefits, which support science and technology infrastructure, science and education infrastructure, and industrial technology innovation infrastructure.This includes R& D institutions, research infrastructure, and innovation-focused industrial parks.

The foundation of this technological development and refers to technology that increases productivity, speed, accuracy, and breadth of information collected, stored, disseminated, and analyzed.This includes 5G, IoT, industrial internet, AI, cloud computing, blockchain, data centers, and internet communication network infrastructure.

Fusion infrastructure formed through the application of internet, big data, AI, and other technologies to support the transformation and upgradation of traditional infrastructure.This includes constructing inter-city high-speed rail and inner-city rail systems, charging stations for electric vehicles (EVs), and ultra-high voltage (UHV) power transmission.

Broadly speaking, these three categories have three main functions

According to estimates from analysts at the CCID Think Tank Electronic Information Institute, a government-affiliated think tank as well as Haitong Securities, a major Chinese securities firm, the investment associated with new infrastructure projects is expected to total around RMB 10 trillion(US$ 1.43 trillion) toRMB 17.5 trillion (US$2.51 trillion) for the next five-year period until 2025.

Since the NDRC clarified the scope of what is new infrastructure, 25 provinces have launched their own local plans.

Among them is the Shanghai plan, which set the total investment target for the next three years at RMB 270 billion (US$38.7 billion), while Guangzhou signed 16 digital new infrastructure projects with a total investment of RMB 56.6 billion (US$8.09 billion). Zhejiang province, home to tech giant Alibaba, also committed to a new batch of projects 61 percent of which are in the high-tech field, a 20 percent increase from the previous year.

Xu Xianping, former deputy director of the NDRC estimates that: the scale of upstream and downstream businesses in the industrial chain will see RMB 2.8 trillion (US$400 billion) in investment, with an average annual growth rate of 22.6 percent.

The same momentum can be seen across different types of technology, where for example, China has announced that by 2025, it will invest RMB 500 billion (US$72 billion) in UHV, RMB 100 billion in AI chips, and RMB 650 billion (US$93.4 billion) in the industrial internet. In terms of 5G networks, China has committed to constructing five million 5G base stations by the end of 2025 a 25-fold increase in less than five years.

Compared to the state-led investment push in traditional infrastructure in the wake of the 2008 global financial crisis, the biggest distinction in the 2020 stimulus package is that this time round the government is much more reliant on market forces and private investment.

Thus, there are many more opportunities for business stakeholders to participate in this next phase of Chinas development.

Still, each sector will see varying degrees of government investment. Consequently, private technology firms will need to assess whether they willing to align their participation with government directives to form partnerships with state-owned-enterprises.

For example, research and satellite communications will have a high government investment ratio, whereas application developments, virtual reality, 3D printing, and smart robot production will typically be comprised of private investments and have relatively low industry barriers for foreign investment.

Ultimately, openness to foreign investment will depend on whether the sector is mentioned in the Special Administrative Measures for Access to Foreign Investment Negative List (2020 Edition) or the Catalogue of Encouraged Industries for Foreign Investment Encouraged List (2019 Edition).

Based on these lists, foreign investment in internet data centers and 5G networks face the most stringent restrictions, while investment in industrial internet, NEVs, and AI are generally perceived to be the most foreign-investment friendly with many upstream and downstream subsectors featured on the encouraged list.

Recently, China also released the exposure draft of its Catalogue of Encouraged Industries for Foreign Investment (2020 Edition), which further encourages foreign-invested enterprises to participate in the high-tech development of its manufacturing industry.

The 2020 draft catalogue proposes to expand the list to include a further 56 items, adding manufacturing of LiDAR (light detection and ranging) and millimeter-wave (MMW) radars related to autonomous driving technology as well as manufacturing of charging piles. In the fields of computer, communication, and electronics manufacturing, the proposed list added manufacturing of smart wearable devices, intelligent unmanned aerial vehicles (UAVs), customer service robots, and smart home systems and equipment.

Though this draft catalogue is still currently undergoing its final round of public consultation, if implemented, it will further open up a range of high-tech sectors to foreign investors.

Foreign-invested enterprises who invest in encouraged industries will be subject to tariff exemptions, preferential land prices, looser regulation of land uses, and lowered corporate income tax. However, those industries that appear on the negative list will either be restricted or prohibited from foreign investment entry.

We will examine seven key sectors of Chinas new infrastructure, and their openness to foreign investment below.

Similar to the trend in other countries, Chinas small and medium-sized enterprises (SMEs) have been a critical driver of innovation, and currently account for approximately 66 percent of the patents issued.

Though direct investment in infrastructure may not be a viable option for SMEs, there are many opportunities either upstream or downstream of the supply chain where they can participate.

There are two sides to the potential opportunities available for SMEs supply and demand. Businesses can either choose to participate in the construction and manufacturing of these new technologies or participate in the commercial application of these technologies across various sectors.

On the supply side, there are other opportunities that exist on the periphery of this large-scale infrastructure build.

For small-to-medium enterprises, many opportunities exist in the upstream (manufacturing of equipment) and downstream (program development) of the industry chain and are encouraged by the government.

Take 5G for example though investment in the network itself is, in practice, an area that is restricted to a few large Chinese players, there are opportunities that exist within the supply chain.

This is particularly true of the automobile industry; for example, 5G network giant Huawei recently announced that it willpartnerwith 18 carmakers, including FAW group, BYD, and T3 Mobility, to build a 5G-enabled automobile ecosystem in the automobile industry moving to accelerate the uptake of 5G technology in smart cars and achieving a significant transformation of its industrial capacity.

Investments into the upstream segment of supply chain attached to 5G networks continue to be in encouraged category for foreign investors, including:

On the demand side, there are a whole array of new use scenarios that will come with the advent of each new type of next-generation technology.

Using the same 5G example, which offers a combination of faster speed, higher capacity, and lower latency this will enable the digitalization of traditional business models. As 5G technology matures, there will be greater opportunities for it to be applied across industries.

Traditional industries, such as medical care, education, retail, manufacturing, services, and logistics will all inevitably have to shift towards digital business models that will adapt to the radical digital transformation or application of new technologies.

For example, CloudMinds Technology, a SoftBank-backed startup in Beijing,donatedrobots with 5G-enabled cloud-based systems to Wuhans hospitals. The robots worked 24/7 hours and undertook jobs like remote nursing, body temperature taking, heart rates and blood oxygen levels measurement, medication delivery, disinfection, and cleaning.

Though there are many opportunities in Chinas tech industry for investors, as the global technology industry becomes increasingly politicized, the challenges may amplify.

As discussed in the Hinrich Foundations report titled Strategic US-China Decoupling in the Tech Sector, the global tech industry continues to see an a heightened sense of techno-nationalism, displayed through a set of mercantilist-like behaviors that link tech innovation and enterprise directly to the national security, economic prosperity and social stability of a nation.

This is especially so as China-US geopolitical competition reaches a tipping point, and mutual tariff hikes, US restriction on exports of high-tech goods and services to China, and targeted restrictions of large tech companies with strong national ties (Huawei and Tiktok) result in an inevitable reshuffling of technological supply chains between the two countries.

Going forward, a much clearer distinction will now be made between foreign and domestic players, a point strongly emphasized by the recent Hinrich Foundation report.

Subsidies, government-backed credit programs for customers, and the Digital Belt and Road Initiative [all] contributed to the meteoric rise of Huawei, and Chinese tech companies in general, the report explains. The US, EU and other state-actors will focus increasingly on countering Beijings economic nationalism with techno-nationalism initiatives of their own.

Countries around the world will continue to be locked in a race to become the first to successfully develop, commercialize, and thus set the standards for the many types of new generation technology that are set to emerge.

Indeed, this is already starting to precipitate with the emergence of the China Standards 2035 Plan, which is an initial blueprint of the standardized processes and specifications to ensure products in the tech industries worldwide are built to work together seamlessly.

Though a growing sense of techno-nationalism will inevitably follow, a complete technology decoupling is unlikely to prevail as technology supply chains still require the participation of many foreign players.

In China, one clear example of this is the semi-conductor industry where China still overwhelmingly relies on foreign companies for its supplies only 16 percent of its semiconductors are produced in the country as of 2019.

Although China has spent billions of dollars in earlier decades to create a domestic semiconductor industry a critical component of the technology supply chain this has come with little success. The chief difficulty for Chinese firms is not access to equipment but their lack of experience and know-how.

Therefore, foreign companies still have a large role to play where current domestic capabilities in Chinas tech industry fall short, particularly, where industries like the semiconductor industry have recently become beneficiaries of a slew of new government preferential policies.

Managers and strategic investors should seek out experts on the ground to craft an appropriate market-entry strategy that accounts for the newly arisen challenges in an increasingly competitive but opportunity-filled landscape.

About Us

China Briefing is written and produced by Dezan Shira & Associates. The practice assists foreign investors into China and has done so since 1992 through offices in Beijing, Tianjin, Dalian, Qingdao, Shanghai, Hangzhou, Ningbo, Suzhou, Guangzhou, Dongguan, Zhongshan, Shenzhen, and Hong Kong.

Please contact the firm for assistance in China at china@dezshira.com. We also maintain offices assisting foreign investors in Vietnam, Indonesia, Singapore, The Philippines, Malaysia,Thailand, United States, and Italy,in addition to our practices in Indiaand Russia and our trade research facilities along the Belt & Road Initiative.

Go here to see the original:

What is China's New Infrastructure Plan and Will it Benefit Tech Investors? - China Briefing

Not just a fad, cloud provides the foundation for future technologies – Federal News Network

This content is provided byRed Hat.

Every year or so, theres a big pushback that labels the cloud as just a fad. One popular argument posits that it doesnt even exist, since its really just someone elses computer. While your average hands-on-keyboards types tend to be more up-to-date on such technologies, its surprisingly common for executives to be less in touch, deciding to skip cloud technologies in favor of seeing what comes next. Within the historical context of IT advances, it becomes clear that this is a mistake; cloud is here to stay, and the next generation of technologies is already being built on its foundations.

There have been a lot of very specific steps over the course of history that have taken us from the mainframe days to where we are now. These steps have shaped our direction into the future, said Damien Eversmann, senior solutions architect for Red Hat Public Sector.

When enterprise IT began with the mainframe, the systems administrators did everything, and the code base was monolithic. But as technology sped up, it diversified, which led to servers. Data sat on one server, business logic on another, and sometimes there would even be a front end presentation layer in the form of a client application, or eventually web browser login. And each of those layers were overseen by a different specialist; as the technology layers diversified, so did the technologists.

Then the number of applications being created continued to grow, Eversmann said. And instead of having people specialize in one layer, people started to break things out into what we now call services oriented architectures. This is the precursor to microservices, one of the main things that were looking at with the cloud now.

Once things started getting broken down into individual services, people realized that those services could be reused. For example, everyone needs a login function. So why not write it once, and share it across all applications?

Now we can scale a much smaller, more granular piece to keep our entire application performing at its best. And this is where making that transition to the cloud was important, Eversmann said. Because the way things were with services oriented architecture, we had reached the limit of what could happen in your data center.

But some people like to point to the pendulum effect around where compute resides to justify waiting until the cloud fad passes. Compute moves from the core, to the edge, back to the core again. From mainframes to workstations to data centers to web browsers.

If the current utilization of cloud is just the pendulum swinging back to the core, albeit one that no longer exists in data centers, why not wait until the pendulum swings back, and skip cloud altogether?

Because it turns out the pendulum metaphor is a little simplistic. Eversmann has a better one.

You know in movies, the ninja that jumps up the alley by jumping back and forth between the buildings? Your pendulum is swinging back and forth but at the same time you keep popping higher and higher, Eversmann said. And thats whats happening here:as we go back and forth between this data at the core, data at the edge, were also leapfrogging the technology of the last time.

In fact, that hypothetical pendulum (or wall-jumping ninja, if you will) is already moving back in the other direction. Technological advancements like the Internet of Things and 5G are enabling so much data to be gathered at the edge that its stressing network bandwidth to send it back to a centralized location for processing. Accordingly, many federal agencies are already looking at and planning for the ability to push compute back out to the edge, so the data gets analyzed in the field where its collected, and the only thing that gets pushed back is the analysis itself.

And youd think that that was a contrary argument to the cloud, right? But its not because if you look at how you define the edge, its actually the cloud, Eversmann said. We now suddenly have the cloud on both sides of this pendulum swing. If we swung into far off servers that are really powerful, thats the cloud. As we need to bring computing closer to the masses, were not bringing it to their desktop anymore. Were bringing it to an edge computing node on the cloud.

Thats why you cant just skip the cloud and see what comes next. Cloud isnt the technology; its the platform.

If you look at some of the functionality and the compute capabilities that live in these hyper-scalers, like AWS or Azure, its stuff that you cant really get in your data center without becoming a hyper-scaler yourself, Eversmann said. There are things that were doing now, with function-based computing and serverless computing that cant be matched without going to the cloud.

Read more:

Not just a fad, cloud provides the foundation for future technologies - Federal News Network